DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+18.6%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.69B
AUM Growth
+$6.69B
(+11%)
Cap. Flow
-$45.5M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
54.02%
Holding
681
New
246
Increased
84
Reduced
73
Closed
235
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$72.1M |
| 2 |
Indivior
INDV
|
$49.7M |
| 3 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$45.7M |
| 4 |
Merus
MRUS
|
$32.9M |
| 5 |
Viatris
VTRS
|
$30.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$102M |
| 2 |
Surgery Partners
SGRY
|
$94.4M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$57.6M |
| 4 |
BioNTech
BNTX
|
$49.8M |
| 5 |
Integra LifeSciences
IART
|
$42.8M |
Sector Composition
| 1 | Healthcare | 87.45% |
| 2 | Industrials | 0.72% |
| 3 | Technology | 0.55% |
| 4 | Financials | 0.42% |
| 5 | Consumer Discretionary | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Dyne Therapeutics
DYN
$1.9B
| $15.6M | 0.23% |
+435,653
| New | +$15.6M |
|
52
Recursion Pharmaceuticals
RXRX
$2.02B
| $15.3M | 0.23% |
+2,315,000
| New | +$15.3M |
|
53
NewAmsterdam Pharma
NAMS
$2.83B
| $15M | 0.22% |
901,750
+32,500
| +4% | +$540K |
|
54
Ventyx Biosciences
VTYX
$181M
| $14.6M | 0.22% |
6,715,501
+885,931
| +15% | +$1.93M |
|
|
CON
55
Concentra Group Holdings Parent, Inc.
CON
$3.05B
| $14.5M | 0.22% |
+650,000
| New | +$14.5M |
|
|
ACCD
56
DELISTED
Accolade, Inc. Common Stock
ACCD
| $13.4M | 0.2% |
3,475,000
| – | – |
|
|
AUTL
57
Autolus Therapeutics
AUTL
$394M
| $13.2M | 0.2% |
3,639,000
| – | – |
|
58
Fate Therapeutics
FATE
$116M
| $12.4M | 0.19% |
3,555,871
| – | – |
|
59
Phreesia
PHR
$1.87B
| $12.4M | 0.19% |
544,448
+352,101
| +183% | +$8.02M |
|
60
Tango Therapeutics
TNGX
$728M
| $11.9M | 0.18% |
1,540,000
| – | – |
|
61
Nkarta
NKTX
$151M
| $9.74M | 0.15% |
2,155,000
-1,644,143
| -43% | -$7.43M |
|
62
Prelude Therapeutics
PRLD
$67.4M
| $7.8M | 0.12% |
3,766,120
-366,880
| -9% | -$759K |
|
63
Alector
ALEC
$278M
| $4.92M | 0.07% |
1,055,192
-93,134
| -8% | -$434K |
|
64
Kyverna Therapeutics
KYTX
$157M
| $4.49M | 0.07% |
918,892
-1,064,108
| -54% | -$5.2M |
|
65
CalciMedica
CALC
$44.6M
| $4.43M | 0.07% |
1,000,000
| – | – |
|
66
Insmed
INSM
$30.6B
| $3.86M | 0.06% |
52,861
+41,502
| +365% | +$3.03M |
|
67
Prime Medicine
PRME
$583M
| $3.47M | 0.05% |
896,960
| – | – |
|
68
Annexon
ANNX
$229M
| $3.46M | 0.05% |
583,913
| – | – |
|
69
HilleVax
HLVX
$105M
| $3.31M | 0.05% |
1,882,654
-2,121,577
| -53% | -$3.73M |
|
|
JBIO
70
Jade Biosciences, Inc. Common Stock
JBIO
$251M
| $2.95M | 0.04% |
1,411,608
| – | – |
|
|
OMIC
71
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $2.6M | 0.04% |
166,162
| – | – |
|
72
Mesa Laboratories
MLAB
$348M
| $2.55M | 0.04% |
19,664
+16,083
| +449% | +$2.09M |
|
73
Albany International
AIN
$1.81B
| $2.39M | 0.04% |
26,848
+14,197
| +112% | +$1.26M |
|
74
Fortrea Holdings
FTRE
$970M
| $2.11M | 0.03% |
+105,470
| New | +$2.11M |
|
75
NVIDIA
NVDA
$4.17T
| $1.98M | 0.03% |
16,318
+5,918
| +57% | +$719K |
|